- Conditions
- Hyperhydrosis, Depression
- Interventions
- Glycopyrrolate
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 17,144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute On Chronic Hepatitis
- Interventions
- ELAD plus standard of care treatment, Standard of care
- Biological · Other
- Lead sponsor
- Vital Therapies, Inc.
- Industry
- Eligibility
- 18 Years to 67 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Menopause, Brain Activity, Cognition
- Interventions
- Lisdexamfetamine, Placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Primary Peritoneal Carcinoma
- Interventions
- Demcizumab, Taxol
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years to 90 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Oklahoma City, Oklahoma • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
- Interventions
- Not listed
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Sickle Cell Disease
- Interventions
- Safety and efficacy assessments
- Other
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- 2 Years to 53 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Oakland, California • Atlanta, Georgia + 12 more
- Conditions
- Hypersomnia
- Interventions
- Sleep study
- Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hydrocephalus, Neurological Disorder
- Interventions
- Hyperfine MRI scan
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- elezanumab, placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more
- Conditions
- Advanced Cancer
- Interventions
- ARRY-334543, EGFR/ErbB2 inhibitor; oral
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Major Depressive Disorder
- Interventions
- Combination Product: BCI-024 + BCI-049
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 9
- States / cities
- Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
- Conditions
- Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma
- Interventions
- Questionnaire Administration, Trametinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 24 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
- Conditions
- Age-Related Maculopathy
- Interventions
- Rheopheresis
- Device
- Lead sponsor
- OccuLogix
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more
- Conditions
- Prostate Cancer
- Interventions
- Xaluritamig, GnRH Antagonist
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- San Francisco, California • St Louis, Missouri • Columbus, Ohio + 4 more
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Interventions
- iNO
- Combination Product
- Lead sponsor
- Bellerophon
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
- Conditions
- Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
- Interventions
- sirolimus
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cesarean Section
- Interventions
- Timing of prophylactic antibiotic administration
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Female only
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
- Interventions
- Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 32
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
- Conditions
- Migraine
- Interventions
- Stimulation of the Occipital Nerves
- Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 8 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Newington, New Hampshire • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- Heart Failure, Congestive
- Interventions
- Seloken ZOK/Toprol-XL, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 41 more
- Conditions
- Pachyonychia Congenita
- Interventions
- PTX-022, Placebo
- Drug
- Lead sponsor
- Palvella Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 6 more